When was CeQur founded?

CeQur was founded in 2008 and raised its 1st funding round 2 years after it was founded.

Where is CeQur located?

CeQur is headquartered in Horw, Switzerland.

How many employees does CeQur have?

As of Aug 31, 2026, the latest employee count at CeQur is 172.

Is CeQur a funded company?

CeQur is a funded company, having raised a total of $492M across 6 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jan 05, 2010.

When was the latest funding round of CeQur?

CeQur's latest funding was a $***** Series E round on Jun 09, 2026, with participation from 0 investor. Its primary sector is Diabetes. In Switzerland, the Diabetes sector has seen $103M in funding in 2026 to date.

Where does CeQur rank among its competitors?

CeQur ranks 1st amongst 94 active competitors, of which 31 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was CeQur, which secured $100M in Jun, 2026.

Who are the top competitors of CeQur?

CeQur's top competitors include Vaxxas, scPharmaceuticals and Hero Patch. Among them, CeQur secured the most recent funding round in June, 2026.

CeQur - 2026 Company Profile, Funding & Competitors

CeQur is a series E company based in Horw (Switzerland), founded in 2008. It operates as a Developer of wearable insulin delivery patch. CeQur has raised $492M in funding from investors like Endeavour Vision, UBS and Schroders. The company has 94 active competitors, including 31 funded and 16 that have exited. Its top competitors include companies like Vaxxas, scPharmaceuticals and Hero Patch.

Company Details

Developer of wearable insulin delivery patch. The company has developed a 3-day bolus device called CeQur Simplicity a wearable insulin patch that delivers injection-free mealtime insulin. The device is made of a cannula to deliver rapid-acting insulin under the skin.

Website: myceqursimplicity.com
Social
Email ID: *****@cequr.com
Phone Number: +41 **********

Key Metrics

Founded Year

2008

Location

Horw, Switzerland

Stage

Series E

Total Funding

$492M in 6 rounds

Latest Funding Round

Series E, Jun 09, 2026, $*****

Investors

Endeavour Vision & 8 more

Ranked

1^st among 94 active competitors

Employee Count

172 as on Aug 31, 2026

Similar Companies

Vaxxas & 118 more

View CeQur's full profile

CeQur has raised a total funding of $492M over 6 rounds. Its first funding round was on Jan 05, 2010. CeQur has 9 institutional investors.

Here is the list of recent funding rounds of CeQur:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 09, 2026	5496551	Series E	7841785	3189316	3911641	1677456
Jan 07, 2025	6445665	Series D	6250185	8632599	4394465	2134754
Apr 13, 2021	7587258	Series C	8503843	7032854	UBS & 1 more	Tandem Diabetes & 4 more

Access funding benchmarks and valuations. Sign up today!

View details of CeQur's funding rounds and investors

CeQur's employee count trend

CeQur has 172 employees as of Aug 26. Here is CeQur's employee count trend over the years:

Uncover CeQur's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CeQur include Vaxxas, scPharmaceuticals and Hero Patch. Here is the list of Top 10 competitors of CeQur, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	CeQur 2008, Horw (Switzerland), Series E	Developer of wearable insulin delivery patch	$492M	Endeavour Vision, Schroders & 7 others	59/100
2nd	Vaxxas 2010, Brisbane (Australia), Series D	Developer of a needle-free patch technology for vaccine delivery applications	$91.2M	One Ventures, UniQuest & 12 others	58/100
3rd	scPharmaceuticals 2013, Lexington (United States), Acquired	Provider of a device for subcutaneous drug delivery for the treatment of bacterial infections and heart failure	$78.7M	Orbimed, Sun Pharma & 4 others	58/100
4th	Hero Patch 2019, Boston (United States), Series A	Developer of antibodies or small molecules for drug delivery	$20.5M	Big Pi Ventures, Velocity Partners & 5 others	55/100
5th	Valeritas 2003, Bridgewater (United States), Acquired	Developer of wearable insulin patch pumps for insulin delivery through the skin	$231M	Welsh, Carson, Anderson & Stowe, Abingworth ... & 12 others	52/100
6th	Starton 2017, New York City (United States), Seed	Developer of drug delivery solution and drugs for treating oncology	$9.29M	LOVE Pharma, Goldfingr	52/100
7th	Corsair Phama 2014, San Francisco (United States), Series B	Developer of drugs for the treatemnt of cardiac diseases	$23M	New Rhein, Primavera & 3 others	51/100
8th	EoFlow 2011, Seongnam-si (South Korea), Acquired	Developer of a wearable disposable insulin patch for diabetes patients	-	Login Investment, LB Investment & 3 others	48/100
9th	NanoPass Technologies 2000, Ness Ziona (Israel), Series C	Microneedles-based device for intradermal delivery	$14.9M	Awz Ventures, Israel HealthCare Ventures & 6 others	48/100
10th	AFYX Therapeutics 2013, Copenhagen (Denmark), Series A	Developer of drug patches for the treatment of mucosal diseases	$33.3M	Sofinnova Investments, Nordic Venture & 6 others	47/100